Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Squires, Kathleen

< Back



Kathleen Squires, MD

Contact Dr. Squires

1015 Chestnut Street
Suite 1020
Philadelphia, PA 19107

(215) 955-7785
(215) 955-9362 fax

Medical School

Medical College of Pennsylvania


Medical College of Pennsylvania (MCP)


Cornell Medical Center - New York Hospital

Board Certification

Internal Medicine
Infectious Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Interests

Dr. Squires joined the Division as Director in September 2005. Her research interests have been concentrated in the field of HIV infection; specifically antiretroviral drug development and identification of novel treatment strategies as well as the course of HIV infection in women. She supervised a three thousand patient HIV clinic and was the Principal Investigator for the USC Clinical Trials Unit at the Keck College of Medicine of the University of Southern California.


Most Recent Peer-Reviewed Publications

  1. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
  2. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
  3. Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
  4. Influence of sex/gender and race on responses to raltegravir combined with tenofovir-emtricitabine in treatment-naive human immunodeficiency virus-1 infected patients: Pooled analyses of the STARTMRK and QDMRK studies
  5. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study
  6. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine
  7. HIV infection: Antiretroviral therapy
  8. Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061
  9. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the hiv reverse transcriptase inhibitor tenofovir, in HIV-infected adults
  10. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women
  11. Bone health and human immunodeficiency virus infection
  12. Insights on GRACE (Gender, Race, and Clinical Experience) from the patient's perspective: GRACE participant survey
  13. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study
  14. Inflammatory biomarker changes and their correlation with framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
  15. Cobicistat: A new boost for the treatment of human immunodeficiency virus infection
  16. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-Week outcomes from GRACE
  17. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women
  18. Gender-sensitive reporting in medical research
  19. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women
  20. ARIES 144 week results: Durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine